Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

SK invests at Ireland pharmaceutical chemical facility

by Rick Mullin
June 25, 2022 | A version of this story appeared in Volume 100, Issue 23

 

The pharmaceutical services firm SK Pharmteco says it will spend $35 million to expand its facility in Swords, Ireland. The project includes a manufacturing building that will add 26.5 m3 of capacity, along with filtration and drying equipment. It is expected to open in 2024. The building will accommodate a second-phase investment with the goal of a 50% capacity expansion at the site, which SK acquired from Bristol Myers Squibb in 2017. SK put $30 million into a reactor expansion at the plant in 2020.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.